Journey Net Income From Continuing Ops from 2010 to 2026

DERM Stock  USD 8.36  0.09  1.07%   
Journey Medical Net Loss yearly trend continues to be very stable with very little volatility. Net Loss is likely to drop to about -13.9 M. During the period from 2010 to 2026, Journey Medical Net Loss quarterly data regression pattern had sample variance of 204.4 T and median of  3,625,000. View All Fundamentals
 
Net Loss  
First Reported
2020-12-31
Previous Quarter
-3.8 M
Current Value
-2.3 M
Quarterly Volatility
7.7 M
 
Covid
 
Interest Hikes
Check Journey Medical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Journey Medical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.2 M, Interest Expense of 4 M or Selling General Administrative of 52.9 M, as well as many indicators such as Price To Sales Ratio of 1.55, Dividend Yield of 0.0 or PTB Ratio of 3.81. Journey financial statements analysis is a perfect complement when working with Journey Medical Valuation or Volatility modules.
  
Build AI portfolio with Journey Stock
Check out the analysis of Journey Medical Correlation against competitors.
Evaluating Journey Medical's Net Income From Continuing Ops across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Journey Medical Corp's fundamental strength.

Latest Journey Medical's Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Journey Medical Corp over the last few years. It is Journey Medical's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Journey Medical's overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

Journey Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(5,069,579)
Geometric Mean6,617,625
Coefficient Of Variation(282.00)
Mean Deviation11,446,867
Median3,625,000
Standard Deviation14,296,288
Sample Variance204.4T
Range49.3M
R-Value(0.62)
Mean Square Error133.3T
R-Squared0.39
Significance0.01
Slope(1,764,581)
Total Sum of Squares3270.1T

Journey Net Income From Continuing Ops History

2026-13.9 M
2025-13.2 M
2024-14.7 M
2023-12.4 M
2022-29.6 M
2021-44 M
20205.3 M

About Journey Medical Financial Statements

Journey Medical investors utilize fundamental indicators, such as Net Income From Continuing Ops, to predict how Journey Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Loss-13.2 M-13.9 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Journey Medical Corp is a strong investment it is important to analyze Journey Medical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Journey Medical's future performance. For an informed investment choice regarding Journey Stock, refer to the following important reports:
Check out the analysis of Journey Medical Correlation against competitors.
You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Will Biotechnology sector continue expanding? Could Journey diversify its offerings? Factors like these will boost the valuation of Journey Medical. Projected growth potential of Journey fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Journey Medical data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(0.35)
Revenue Per Share
2.577
Quarterly Revenue Growth
0.205
Return On Assets
(0.05)
Return On Equity
(0.47)
Understanding Journey Medical Corp requires distinguishing between market price and book value, where the latter reflects Journey's accounting equity. The concept of intrinsic value—what Journey Medical's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Journey Medical's price substantially above or below its fundamental value.
It's important to distinguish between Journey Medical's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Journey Medical should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Journey Medical's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.